Gastrointestinal tumors - Interdisciplinary discussion of new data;Gastrointestinale Tumore - interdisziplinäre Diskussion neuer Daten

Onkologie

Volumn 34, Issue SUPPL. 3, 2011, Pages 1-31

  Arnold, Dirk ^a   Fietkau, Rainer ^b   Hegewisch Becker, Susanna ^c   Höhler, Thomas ^d   Knoefel, Wolfram Trudo ^e   Kubicka, Stefan ^f   Lang, Hauke ^g   Liersch, Torsten ^h   Luster, Markus ⁱ   Oettle, Helmut ^j   Reinacher Schick, Anke ^k   Ridwelski, Karsten ^l   Riess, Hanno ^j   Rödel, Claus ^m   Rüschoff, Josef ⁿ   Schmiegel, Wolff ^k   Schmoll, Hans Joachim ^o   Vanhoefer, Udo ^p  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c Onkologische Schwerpunktpraxis   (Germany)

^d PROSPER HOSPITAL   (Germany)

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

ⁱ UNIVERSITY OF ULM   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k RUHR UNIVERSITY BOCHUM   (Germany)

^l Klinikum Magdeburg   (Germany)

^m GOETHE UNIVERSITY   (Germany)

ⁿ TARGOS Molecular Pathology GmbH   (Germany)

^o MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^p Zentrum fur Innere Medizin   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RESEARCH; DISEASE COURSE; GASTROINTESTINAL TUMOR;

EID: 79957480536     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000328047     Document Type: Article

References (161)

1. Andre T et al.; Multicenter International Study of Oxaliplatin/5- Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
2. Kuebler JP et al.: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198-2204. (Pubitemid 46954643)
3. Haller DG et al.: NO16968: XELOXA. Adjuvant treatment with capecitabine and oxaliplatin (XELOX) in stage III colon cancer. Eur J Cancer Suppl 2009;7:4, abstr 5LBA.
4. Twelves C et al.: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704. (Pubitemid 41007824)
5. André T et al.: Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003;21:2896-2903. (Pubitemid 46621839)
6. Lumley T: Network meta-analysis for indirect treatment comparisons. Stat Med 2002;21:2313-2324.
7. Cassidy J, Schmoll H-J, Chu E, et al.: Comparative clinical efficacy of adjuvant chemotherapy regimens in randomized controlled trials of early-stage colon cancer: systematic review and meta-analysis. ASCO GI 2011, abstr 498.
8. Schmoll H-J et al.: Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007;25:102-109. (Pubitemid 350003057)
9. Schmiegel W et al.: S3-Leitlinie «Kolorektales Karzinom » - Aktualisierung 2008. Z Gastroenterol 2008;46:799-840.
10. Schmiegel W et al.: Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases. Dtsch Arztebl Int 2009; 106:843-848.
11. McCleary J et al.: Impact of older age on the efficacy of newer adjuvant therapies in >12 500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT database. J Clin Oncol 2009; 27(suppl):15s, abstr 4010.
12. André T et al.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-3116.
13. Van Cutsem E et al.: Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27:3117-3125.
14. Saltz LB et al.: Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25:3456-3461. (Pubitemid 47310883)
15. Lembersky BC et al.: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006;24:2059-2064. (Pubitemid 46622115)
16. Twelves C et al.: Capecitabine versus 5-FU/LV in stage III colon cancer: Updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy. ASCO GI 2008, abstr 274.
17. Haller DG et al.: Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact of age on disease-free survival (DFS). ASCO GI 2010, abstr 284.
18. Cassidy J et al.: Review of completed and ongoing trials of capecitabine-based adjuvant therapy in patients with early-stage colon cancer. ASCO GI 2011, abstr 495.
19. Ychou M et al.: A phase III randomized trial of LV5FU2 + CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/ FFCD9802). ASCO 2005, abstr 3502.
20. Alberts SR et al.: Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. ASCO 2010, abstr CRA 3507.
21. Goldberg RM et al.: Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. ASCO 2010, abstr 3508.
22. Huang J et al.: Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147. ASCO GI 2011, abstr 363.
23. Wolmark N et al.: A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol 2009 27 (suppl):18s, abstr LBA4.
24. De Gramont A et al.: AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. ASCO GI 2011, abstr 362.
25. Biagi JJ et al.: The impact of time to adjuvant chemotherapy on survival in colorectal cancer: A systematic review and meta-analysis. ASCO GI 2011, abstr 364.
26. Salazar R et al.: Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011;29:17-24.
27. Rosenberg R et al.: Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer patients. ASCO GI 2011, abstr 358.
28. Kerr D et al.: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009;27(suppl):15s, abstr 4000.
29. Quasar Collaborative Group: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370: 2020-2029.
30. Roth AD, Tejpar S, Yan P, et al.: Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol 2009;27(suppl):15s, abstr 4002.
31. Roth AD, Tejpar S, Delorenzi M, et al.: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-474.
32. Popat S et al.: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-618. (Pubitemid 46224239)
33. Meropol NJ et al.: Use of a multigene prognostic assay for selection of adjuvant chemotherapy in patients with stage II colon cancer: Impact on qualityadjusted life expectancy and costs. ASCO GI 2011, abstr 491.
34. Ribic CM et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-257. (Pubitemid 36859476)
35. Jover R et al.: The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009;45:365-373.
36. Sargent DJ et al.: Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. ASCO 2008, abstr 4008.
37. Tejpar S et al.: Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol 2009;27 (suppl):15s, abstr 4001.
38. Pogue-Geile KL et al.: Use of a prognostic (prog) gene index and nodal status to identify a subset of stage II and III colon cancer patients (pts) who may not need oxaliplatin (ox)-containing adjuvant chemotherapy. J Clin Oncol 2010;28(suppl):15s, abstr 3516.
39. Hohenberger W et al.: Standardized surgery for colonic cancer: complete mesocolic excision and central ligation - technical notes and outcome. Colorectal Dis 2009;11:354-364.
40. West NP, Hohenberger W, et al.: Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 2010;28:272-278.
41. West NP: Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. Lancet Oncol 2008; 9:857-865.
42. Koopman M et al.: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007;370:135-142. (Pubitemid 47042893)
43. Seymour MT et al.: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007;370:143-152. (Pubitemid 47042894)
44. Sargent DJ et al.: Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 2009;27:1948-1955.
45. Souglakos J et al.: FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94:798-805.
46. Falcone A et al.; for the Gruppo Oncologico Nord Ovest: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer. J Clin Oncol 2007; 25:1670-1676. (Pubitemid 46797946)
47. Masi G et al.: Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-852.
48. Folprecht G et al.: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38-47.
49. Van Cutsem E et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
50. Bokemeyer C et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the firstline treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.
51. Maughan TS et al.: Oxaliplatin and fluoropyrimidine chemotherapy plus or minus cetuximab: The effect of infusional 5-FU or capecitabine on the outcomes of the MRC COIN trial in advanced colorectal cancer (ACRC). ASCO GI 2010, abstr 402.
52. Tveit K et al.: Randomized phase III study of 5-fluorouracil/folinate/ oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. ASCO GI 2011, abstr 365.
53. Kopetz S: Phase IB STUDY of the src inhibitor dasatinib with FOLFOX and cetuximab in refractory metastatic colorectal cancer. GI ESMO 2010, Ann Oncol 2010;21 (Suppl 6): vi11-vi19.
54. Hurwitz H et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. (Pubitemid 38702844)
55. Fuchs CS, Marshall J, Mitchell E, et al.: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study. J Clin Oncol 2007;25:4779-4786. (Pubitemid 350086481)
56. Fuchs C et al.: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008;26:689-690. (Pubitemid 351264373)
57. Hecht JR et al.: Interim results from PACCE: Irinotecan / bevacizumab +/- panitumumab as firstline treatment for metastatic colorectal cancer. ASCO GI 2008, abstr 279.
58. Hecht JR et al.: An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). ASCO GI 2008, abstr 273.
59. Punt CJ et al.: Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). ASCO 2008, abstr LBA4011.
60. Schmoll H-J et al.: mFOLFOX6 + cediranib versus mFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer: a randomized, double-blind, phase II/III study (HORIZON III). ESMO 2010, Ann Oncol 2010;21(suppl 8).
61. Saltz LB et al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-2019.
62. Erratum in: J Clin Oncol 2008;26:3110.
63. Tebbutt NC et al.: International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): final results of the AGITG MAX trial. ESMO 2009, abstr 6001.
64. Kabbinavar FF et al.: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/ leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23: 3706-3712.
65. Eng C et al.: Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial. ASCO 2007, abstr 4003.
66. Au H: Quality of life in patients with advanced colorectal cancer treated with cetuximab: Results of the NCIC CTG and AGITG CO.17 trial. ASCO 2007, abstr 4002.
67. Amado RG et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
68. Peeters M et al.: Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results. J Clin Oncol 2008;26(suppl):abstr 4064.
69. Adams R et al.: Intermittent versus continuous oxaliplatin- fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial. ASCO 2010, abstr 3525.
70. Tabernero J et al.: Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO trial. ASCO 2010, abstr 3501.
71. Murukesh N et al.: Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102:8-18.
72. de Bazelaire C et al.: Magnetic resonance imagingmeasured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 2008;14:5548-5554.
73. Chun YS, Vauthey JN, et al.: Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009;302:2338-2344.
74. Bokemeyer C et al.: Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. ASCO 2010, abstr 3506.
75. Nordlinger B et al.: Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009;20:985-992.
76. Fong Y et al.: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-318, discussion 318-321.
77. Nordlinger B, Sorbye H, Glimelius B et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-1016. (Pubitemid 351392040)
78. Portier G et al.: Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006;24:4976-4982. (Pubitemid 46631399)
79. Langer B et al.: Fluorouracil (FU) plus L-leucovorin (L-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 2002;21:abstr 592.
80. Mitry E et al.: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008;26:4906-4911.
81. Van Cutsem E et al.: Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. ASCO GI 2010, abstr 281.
82. Cassidy J et al.: Surgery with curative intent in patients treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966. ASCO 2008, abstr 4022.
83. Ribero D et al.: Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007;110: 2761-2767. (Pubitemid 350250347)
84. Kishi Y et al.: Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010;17:2870-2876.
85. Grünberger B et al.: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008;26:1830-1835.
86. Grünberger T et al.: Progression-free survival in a phase II study of perioperative bevacizumab plus XELOX in patients with potentially curable metastatic colorectal cancer. ASCO 2008, abstr 4073.
87. Masi G et al.: Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009;249:420-425.
88. Garufi C et al.: POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/ leucovorin(FA)/ oxaliplatin (L-OHP) (CPT-11- FFL) in unresectable colorectal liver metastases (CLM). ASCO 2009, abstr e15020.
89. Ychou M et al.: Preliminary results of a multicentre phase II trial evaluating cetuximab in combination with FOLFIRINOX (LV5FU + irinotecan + oxaliplatin) as first line treatment of metastatic colorectal cancer (mCRC) patients. ASCO GI 2009, abstr 450.
90. Folprecht G et al.: Cetuximab and FOLFOXIRI: Dose-escalation study in previously untreated patients with metastatic colorectal cancer. ASCO GI 2010, abstr 480.
91. Berry D et al.: Personalized Medicine: How redesigning a clinical trial can speed drug development. Wall Street Journal, October 2010.
92. Gerard JP, Conroy T, Bonnetain F, et al.: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620-4625. (Pubitemid 46630960)
93. Bosset JF; for the EORTC Radiotherapy Group Trial 22921: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355:1114-1123.
94. Sauer R et al.: Preoperative vs. postoperative chemoradiotherapy for rectal cancer. New Engl J Med 2004;351:1731-1740.
95. Collette L et al.: Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007;25:4379-4386.
96. Collette L et al.: Correspondence. J Clin Oncol 2008;26:508-509.
97. Cionini L et al.: Final results of a randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. Radiother Oncol 2010;96(suppl 1):abstr 299.
98. Maas M et al.: Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11:835-844.
99. Dewdney A et al.: EXPERT-C: A randomized phase II European multicenter trial of neoadjuvant chemotherapy (capecitabine/oxaliplatin) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined high-risk rectal cancer. ASCO GI 2011, abstr 360.
100. Rödel C et al.: Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007;25:110-117. (Pubitemid 350003058)
101. Sebag-Montefiori DJ et al.: Three-year survival results of CORE (capecitabine, oxaliplatin, radiotherapy, and excision) study after postoperative chemotherapy in patients with locally advanced rectal adenocarcinoma. abstr 447.
102. Fernández-Martos C et al.: Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging- defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 study. J Clin Oncol 2010;28:859-865.
103. Schrag D et al.: Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. ASCO 2010, abstr 3511.
104. Chau I et al.: Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006;24:668-674. (Pubitemid 46630432)
105. Chua YJ et al.: Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010; 11:241-248.
106. Kundel Y et al.: Is local excision after complete pathological response to neoadjuvant chemoradiation for rectal cancer an acceptable treatment option? Dis Colon Rectum 2010;53:1624-1631.
107. Habr-Gama A et al.: Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 2010;53:1692-1698.
108. Hiotis SP et al.: Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 2002;194:131-135, discussion 135-136.
109. Habr-Gama A et al.: Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240:711-717, discussion 717-718.
110. Habr-Gama A et al.: Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Dis 2006;8(suppl 3):21-24.
111. Yeo SG et al.: Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). Ann Surg 2010;252:998-1004.
112. Liersch T et al.: Molekulare Marker zur Responseprädiktion beim lokal fortgeschrittenen Rektumkarzinom. Kommt die Individualisierung der Therapie? Der Onkologe 2010;16:779-788.
113. Sprenger T et al.: Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification? World J Surg Oncol 2010;8:27.
114. Sprenger T et al.: Preoperative chemoradiotherapy does not necessarily reduce lymph node retrieval in rectal cancer specimens - results from a prospective evaluation with extensive pathological work-up. J Gastrointest Surg 2010;14:96-103.
115. Gaedcke J et al.: KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 2010; 94:76-81.
116. Gaedcke J et al.: Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer 2010;49:1024-1034.
117. Opitz L et al.: Impact of RNA degradation on gene expression profiling. BMC Med Genomics 2010;3:36.
118. Conradi LC et al.: Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment. Ann Surg Oncol 2011; DOI: 10.1245/S10434-011-1605-4
119. Sprenger T et al.: Failure of down-regulation of Survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival. Clin Cancer Res 2011;17:1623-1631.
120. Bujko K et al.: Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93:1215-1223. (Pubitemid 44547018)
121. Fietkau R et al.: Letter to the editor. Br J Cancer 2007.
122. Lange MM et al.: Risk factors for sexual dysfunction after rectal cancer treatment. Eur J Cancer 2009;45:1578-1588.
123. Ngan S et al.: A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS). ASCO 2010, abstr 3509.
124. Pietsch AP et al.: Effect of neoadjuvant chemoradiation on postoperative fecal continence and anal sphincter function in rectal cancer patients. Int J Colorectal Dis 2007;22:1311-1317. (Pubitemid 47456715)
125. Chowdhury FU et al.: [18F]FDG PET/CT imaging of colorectal cancer: a pictorial review. Postgrad Med J 2010;86:174-182.
126. Hillner BE et al.: The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer 2009;115:410- 418.
127. Erratum in: Cancer 2009;115:1133.
128. Weber WA et al.: Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med 2007;48(suppl 1):36S-44S. (Pubitemid 47604941)
129. Wahl RL et al.: From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(suppl 1): 122S-150S.
130. Joosten J et al.: Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. Eur J Surg Oncol 2005;31:1152-1159. (Pubitemid 41819201)
131. Kang YK et al.: AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). ASCO 2010, abstr LBA4007.
132. Enzinger PC et al.: CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. ASCO 2010, abstr 4006.
133. Bang Y-J et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
134. European Medicines Agency vom 28.1.2010. S3-Leitlinie Magenkarzinom, vorgestellt auf dem Deutschen Krebskongress, Berlin, 24. Februar 2010
135. Bang Y et al.: Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009;27(suppl):15s, abstr 4556.
136. Rüschoff J et al.: HER2 diagnostics in gastric cancer - Guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299-307.
137. Schuhmacher C et al.: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010;28:5210-5218.
138. Cunningham D et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
139. Moore MJ et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966. (Pubitemid 46972777)
140. Van Cutsem E et al.: Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA study. ASCO GI 2009, abstr 117.
141. Boeck SH et al.: Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). ASCO 2010, abstr LBA4011.
142. Conroy T et al.: Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. ASCO 2010, abstr 4010.
143. Pelzer U et al.: A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. ASCO 2008, abstr 4508.
144. Lin SM et al.: Randomised controlled trial comparing percutaneous
145. Shiina S et al.: A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122-130. (Pubitemid 41002049)
146. Llovet JM et al.: Hepatocellular carcinoma. Lancet 2003;362:1907-1917. (Pubitemid 37518510)
147. Salem R et al.: Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497-507.
148. Zender L, Kubicka S: Molecular pathogenesis and targeted therapy of hepatocellular carcinoma. Onkologie 2008;31:550-555.
149. Llovet JM et al; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
150. Cheng AL et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
151. Thomas MB et al.: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843-850.
152. Abou-Alfa GK et al.: Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC). ASCO GI 2008, abstr 128.
153. Abou-Alfa GK et al.: Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? ASCO 2008, abstr 4518.
154. Gebski V et al.: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-234. (Pubitemid 46291702)
155. Urschel JD et al.: A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185:538-543. (Pubitemid 36627845)
156. Gaast AV et al.: Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. ASCO 2010, abstr 4004.
157. Mariette C et al.: Surgery alone vs. chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial. FFCD 9901. ASCO 2010, abstr 4005.
158. Stahl M et al.: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-2317. (Pubitemid 46218723)
159. Bedenne L et al.: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160-1168. (Pubitemid 46640561)
160. Stahl M et al.: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-856.
161. Schauer M et al.: Microarray-based response prediction in esophageal adenocarcinoma. Clin Cancer Res 2010;16:330-337.